Do analysts prefer NKGN or KYNB?

Kyntra Bio has a consensus price target of $32.50, indicating a potential upside of 362.30%. Given Kyntra Bio's stronger consensus rating and higher probable upside, analysts clearly believe Kyntra Bio is more favorable than NKGen Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NKGen Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Kyntra Bio 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60

Is NKGN or KYNB more profitable?

Kyntra Bio has a net margin of 2,199.13% compared to NKGen Biotech's net margin of 0.00%. Company Net Margins Return on Equity Return on Assets NKGen Biotech N/A N/A -479.36% Kyntra Bio 2,199.13% N/A -36.71%

Do analysts rate DARE or NKGN?

Dare Bioscience currently has a consensus target price of $10.00, indicating a potential upside of 681.25%. Given Dare Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Dare Bioscience is more favorable than NKGen Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dare Bioscience 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 NKGen Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is DARE or NKGN more profitable?

Company Net Margins Return on Equity Return on Assets Dare Bioscience N/A N/A -46.22% NKGen Biotech N/A N/A -479.36%

Is ATNM or NKGN more profitable?

NKGen Biotech's return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Actinium Pharmaceuticals N/A -100.85% -47.89% NKGen Biotech N/A N/A -479.36%

Do analysts prefer NKGN or TVRD?

Tvardi Therapeutics has a consensus price target of $19.67, suggesting a potential upside of 683.53%. Given Tvardi Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tvardi Therapeutics is more favorable than NKGen Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NKGen Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Tvardi Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78

Which has better valuation & earnings, NKGN or TVRD?

Tvardi Therapeutics is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NKGen Biotech N/A N/A -$82.94M -$1.68 N/A Tvardi Therapeutics N/A N/A -$18.21M -$3.10 N/A

Is NKGN or TVRD more profitable?

NKGen Biotech's return on equity of 0.00% beat Tvardi Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets NKGen Biotech N/A N/A -479.36% Tvardi Therapeutics N/A -64.17% -43.90%

Do analysts prefer BGM or NKGN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NKGen Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation and earnings, BGM or NKGN?

BGM Group has higher revenue and earnings than NKGen Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BGM Group $37.92M 0.74 -$1.44M N/A N/A NKGen Biotech N/A N/A -$82.94M -$1.68 N/A

Is BGM or NKGN more profitable?

Company Net Margins Return on Equity Return on Assets BGM Group N/A N/A N/A NKGen Biotech N/A N/A -479.36%

NKGen Biotech (NKGN) Competitors

$0.06 0.00 (0.00%)

As of 07/24/2026

Compare

NKGN vs. KYNB, DARE, ATNM, TVRD, and BGM

Should you buy NKGen Biotech stock or one of its competitors? MarketBeat compares NKGen Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NKGen Biotech include Kyntra Bio (KYNB), Dare Bioscience (DARE), Actinium Pharmaceuticals (ATNM), Tvardi Therapeutics (TVRD), and BGM Group (BGM). These companies are all part of the "pharmaceutical products" industry.

How does NKGen Biotech compare to Kyntra Bio?

NKGen Biotech (NYSE:NKGN) and Kyntra Bio (NASDAQ:KYNB) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

Kyntra Bio has a consensus price target of $32.50, indicating a potential upside of 362.30%. Given Kyntra Bio's stronger consensus rating and higher probable upside, analysts clearly believe Kyntra Bio is more favorable than NKGen Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NKGen Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

76.2% of NKGen Biotech shares are held by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are held by institutional investors. 10.4% of NKGen Biotech shares are held by insiders. Comparatively, 4.2% of Kyntra Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Kyntra Bio has a net margin of 2,199.13% compared to NKGen Biotech's net margin of 0.00%.

Company	Net Margins	Return on Equity	Return on Assets
NKGen Biotech	N/A	N/A	-479.36%
Kyntra Bio	2,199.13%	N/A	-36.71%

NKGen Biotech has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market. Comparatively, Kyntra Bio has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market.

In the previous week, Kyntra Bio had 1 more articles in the media than NKGen Biotech. MarketBeat recorded 1 mentions for Kyntra Bio and 0 mentions for NKGen Biotech. Kyntra Bio's average media sentiment score of 1.87 beat NKGen Biotech's score of 0.00 indicating that Kyntra Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
NKGen Biotech	Neutral
Kyntra Bio	Very Positive

Kyntra Bio has higher revenue and earnings than NKGen Biotech. NKGen Biotech is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NKGen Biotech	N/A	N/A	-$82.94M	-$1.68	N/A
Kyntra Bio	$7.44M	3.83	$183.45M	$40.46	0.17

Summary

Kyntra Bio beats NKGen Biotech on 13 of the 15 factors compared between the two stocks.

How does NKGen Biotech compare to Dare Bioscience?

Dare Bioscience (NASDAQ:DARE) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

6.7% of Dare Bioscience shares are owned by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are owned by institutional investors. 4.1% of Dare Bioscience shares are owned by insiders. Comparatively, 10.4% of NKGen Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Dare Bioscience has higher revenue and earnings than NKGen Biotech. Dare Bioscience is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.03M	18.74	-$13.40M	-$0.95	N/A
NKGen Biotech	N/A	N/A	-$82.94M	-$1.68	N/A

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	N/A	N/A	-46.22%
NKGen Biotech	N/A	N/A	-479.36%

Dare Bioscience has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market. Comparatively, NKGen Biotech has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market.

Dare Bioscience currently has a consensus target price of $10.00, indicating a potential upside of 681.25%. Given Dare Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Dare Bioscience is more favorable than NKGen Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
NKGen Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Dare Bioscience had 4 more articles in the media than NKGen Biotech. MarketBeat recorded 4 mentions for Dare Bioscience and 0 mentions for NKGen Biotech. Dare Bioscience's average media sentiment score of 0.56 beat NKGen Biotech's score of 0.00 indicating that Dare Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Dare Bioscience	Positive
NKGen Biotech	Neutral

Summary

Dare Bioscience beats NKGen Biotech on 10 of the 13 factors compared between the two stocks.

How does NKGen Biotech compare to Actinium Pharmaceuticals?

Actinium Pharmaceuticals (NYSE:ATNM) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

NKGen Biotech's return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
NKGen Biotech	N/A	N/A	-479.36%

Actinium Pharmaceuticals has higher revenue and earnings than NKGen Biotech. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$90K	299.81	-$48.82M	-$0.75	N/A
NKGen Biotech	N/A	N/A	-$82.94M	-$1.68	N/A

27.5% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are held by institutional investors. 0.6% of Actinium Pharmaceuticals shares are held by insiders. Comparatively, 10.4% of NKGen Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Actinium Pharmaceuticals had 1 more articles in the media than NKGen Biotech. MarketBeat recorded 1 mentions for Actinium Pharmaceuticals and 0 mentions for NKGen Biotech. Actinium Pharmaceuticals' average media sentiment score of 0.75 beat NKGen Biotech's score of 0.00 indicating that Actinium Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Actinium Pharmaceuticals	Positive
NKGen Biotech	Neutral

Actinium Pharmaceuticals has a beta of -0.02, suggesting that its share price is 102% less volatile than the broader market. Comparatively, NKGen Biotech has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market.

Actinium Pharmaceuticals presently has a consensus target price of $5.00, suggesting a potential upside of 481.40%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Actinium Pharmaceuticals is more favorable than NKGen Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
NKGen Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Actinium Pharmaceuticals beats NKGen Biotech on 9 of the 14 factors compared between the two stocks.

How does NKGen Biotech compare to Tvardi Therapeutics?

NKGen Biotech (NYSE:NKGN) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

Tvardi Therapeutics is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NKGen Biotech	N/A	N/A	-$82.94M	-$1.68	N/A
Tvardi Therapeutics	N/A	N/A	-$18.21M	-$3.10	N/A

NKGen Biotech's return on equity of 0.00% beat Tvardi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NKGen Biotech	N/A	N/A	-479.36%
Tvardi Therapeutics	N/A	-64.17%	-43.90%

NKGen Biotech has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market. Comparatively, Tvardi Therapeutics has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market.

Tvardi Therapeutics has a consensus price target of $19.67, suggesting a potential upside of 683.53%. Given Tvardi Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tvardi Therapeutics is more favorable than NKGen Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NKGen Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

76.2% of NKGen Biotech shares are owned by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are owned by institutional investors. 10.4% of NKGen Biotech shares are owned by company insiders. Comparatively, 7.4% of Tvardi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Tvardi Therapeutics had 2 more articles in the media than NKGen Biotech. MarketBeat recorded 2 mentions for Tvardi Therapeutics and 0 mentions for NKGen Biotech. Tvardi Therapeutics' average media sentiment score of 0.99 beat NKGen Biotech's score of 0.00 indicating that Tvardi Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
NKGen Biotech	Neutral
Tvardi Therapeutics	Positive

Summary

Tvardi Therapeutics beats NKGen Biotech on 8 of the 14 factors compared between the two stocks.

How does NKGen Biotech compare to BGM Group?

BGM Group (NASDAQ:BGM) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

BGM Group has a beta of 1.78, meaning that its share price is 78% more volatile than the broader market. Comparatively, NKGen Biotech has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market.

In the previous week, BGM Group had 3 more articles in the media than NKGen Biotech. MarketBeat recorded 3 mentions for BGM Group and 0 mentions for NKGen Biotech. BGM Group's average media sentiment score of 0.30 beat NKGen Biotech's score of 0.00 indicating that BGM Group is being referred to more favorably in the media.

Company	Overall Sentiment
BGM Group	Neutral
NKGen Biotech	Neutral

76.2% of NKGen Biotech shares are held by institutional investors. 58.7% of BGM Group shares are held by insiders. Comparatively, 10.4% of NKGen Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
BGM Group	N/A	N/A	N/A
NKGen Biotech	N/A	N/A	-479.36%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NKGen Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

BGM Group has higher revenue and earnings than NKGen Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BGM Group	$37.92M	0.74	-$1.44M	N/A	N/A
NKGen Biotech	N/A	N/A	-$82.94M	-$1.68	N/A

Summary

BGM Group beats NKGen Biotech on 8 of the 9 factors compared between the two stocks.

Get NKGen Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NKGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NKGN vs. The Competition

Export

Metric	NKGen Biotech	Biological Products Industry	Medical Sector	NYSE Exchange
Market Cap	$7.84M	$357.18M	$6.87B	$23.47B
Dividend Yield	N/A	N/A	2.67%	4.20%
P/E Ratio	-0.01	N/A	27.14	30.75
Price / Sales	N/A	228.84	517.06	166.31
Price / Cash	N/A	22.44	50.54	31.69
Price / Book	-0.02	4.88	10.28	4.73
Net Income	-$82.94M	-$141.03M	$3.60B	$1.07B
7 Day Performance	N/A	-1.69%	-1.27%	-0.45%
1 Month Performance	N/A	0.21%	-0.37%	0.72%
1 Year Performance	N/A	39.82%	18.30%	14.09%

NKGen Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NKGN NKGen Biotech	N/A	$0.06 flat	N/A	-68.4%	$7.84M	N/A	N/A	N/A
KYNB Kyntra Bio	4.1427 of 5 stars	$7.23 -2.2%	$32.50 +349.5%	N/A	$29.92M	$6.44M	0.18	570	Positive News
DARE Dare Bioscience	2.88 of 5 stars	$1.96 +1.0%	$10.00 +410.2%	-51.3%	$29.06M	$1.16M	N/A	30
ATNM Actinium Pharmaceuticals	2.3655 of 5 stars	$0.92 +3.6%	$5.00 +442.4%	-52.7%	$28.93M	$90K	N/A	30
TVRD Tvardi Therapeutics	2.8891 of 5 stars	$3.20 +3.9%	$19.67 +514.6%	-90.8%	$28.90M	$7.14M	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NKGN) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NKGen Biotech (NKGN) Competitors

NKGN vs. KYNB, DARE, ATNM, TVRD, and BGM

How does NKGen Biotech compare to Kyntra Bio?

Summary

How does NKGen Biotech compare to Dare Bioscience?

Summary

How does NKGen Biotech compare to Actinium Pharmaceuticals?

Summary

How does NKGen Biotech compare to Tvardi Therapeutics?

Summary

How does NKGen Biotech compare to BGM Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKGN vs. The Competition

NKGen Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NKGen Biotech (NKGN) Competitors

NKGN vs. KYNB, DARE, ATNM, TVRD, and BGM

How does NKGen Biotech compare to Kyntra Bio?

Do analysts prefer NKGN or KYNB?

Do insiders & institutionals hold more shares of NKGN or KYNB?

Is NKGN or KYNB more profitable?

Which has more risk & volatility, NKGN or KYNB?

Does the media favor NKGN or KYNB?

Which has stronger earnings and valuation, NKGN or KYNB?

Summary

How does NKGen Biotech compare to Dare Bioscience?

Do insiders and institutionals believe in DARE or NKGN?

Which has higher valuation & earnings, DARE or NKGN?

Is DARE or NKGN more profitable?

Which has more volatility and risk, DARE or NKGN?

Do analysts rate DARE or NKGN?

Does the media refer more to DARE or NKGN?

Summary

How does NKGen Biotech compare to Actinium Pharmaceuticals?

Is ATNM or NKGN more profitable?

Which has preferable valuation & earnings, ATNM or NKGN?

Do insiders & institutionals have more ownership in ATNM or NKGN?

Does the media refer more to ATNM or NKGN?

Which has more volatility & risk, ATNM or NKGN?

Do analysts recommend ATNM or NKGN?

Summary

How does NKGen Biotech compare to Tvardi Therapeutics?

Which has better valuation & earnings, NKGN or TVRD?

Is NKGN or TVRD more profitable?

Which has more risk & volatility, NKGN or TVRD?

Do analysts prefer NKGN or TVRD?

Do institutionals and insiders hold more shares of NKGN or TVRD?

Does the media prefer NKGN or TVRD?

Summary

How does NKGen Biotech compare to BGM Group?

Which has more volatility & risk, BGM or NKGN?

Does the media refer more to BGM or NKGN?

Do institutionals and insiders believe in BGM or NKGN?

Is BGM or NKGN more profitable?

Do analysts prefer BGM or NKGN?

Which has higher valuation and earnings, BGM or NKGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKGN vs. The Competition

NKGen Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools